These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 34084144)

  • 1. A Biosimilarity Study Between QX001S and Ustekinumab in Healthy Chinese Male Subjects.
    Gao L; Li Q; Zhang H; Wu M; Fang M; Yang L; Li X; Liu J; Li C; Chen H; Zhu X; Ding Y; Zhou M
    Front Pharmacol; 2021; 12():675358. PubMed ID: 34084144
    [No Abstract]   [Full Text] [Related]  

  • 2. A phase I study comparing the biosimilarity of the pharmacokinetics and safety of recombinant humanized anti-vascular endothelial growth factor monoclonal antibody injection with Avastin
    Li H; Zhao X; Xie J; Zhu X; Su Y; He C; Ding J; Zhu M; Xu Y; Wang Y; Shan R; Liu B; Ding Y; Liu Y; Zhou H; Xie Y
    BMC Pharmacol Toxicol; 2023 May; 24(1):36. PubMed ID: 37245022
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Phase I Clinical Study Comparing the Tolerance, Immunogenicity, and Pharmacokinetics of Proposed Biosimilar BAT1806 and Reference Tocilizumab in Healthy Chinese Men.
    Zhang H; Wang H; Wei H; Chen H; Liu J; Li C; Zhu X; Li X; Yu J; Zhou Y; Yang X; Wang Z; Wu M; Ding Y
    Front Pharmacol; 2020; 11():609522. PubMed ID: 33569002
    [No Abstract]   [Full Text] [Related]  

  • 4. Comparative Pharmacokinetics, Bioequivalence and Safety Study of Two Recombinant Human Chorionic Gonadotropin Injections in Healthy Chinese Subjects.
    Wang J; Yang T; Mei H; Yu X; Peng H; Wang R; Cai Y
    Drug Des Devel Ther; 2020; 14():435-444. PubMed ID: 32099328
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized, double-blind, parallel-group, single‑dose, pharmacokinetic bioequivalence study of INTP24 and bevacizumab in healthy adult men.
    Singh I; Patel R; Patel A; Jose V
    Cancer Chemother Pharmacol; 2020 Aug; 86(2):193-202. PubMed ID: 32627073
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetic Profiles of a Proposed Biosimilar Ustekinumab (BFI-751): Results From a Randomized Phase 1 Trial.
    Hausfeld JN; Challand R; McLendon K; Macapagal N; Bruce-Staskal P; Fiaschetti C; Sampey DB
    Clin Pharmacol Drug Dev; 2023 Oct; 12(10):1001-1012. PubMed ID: 37483071
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of the pharmacokinetics of subcutaneous ustekinumab between Chinese and non-Chinese healthy male subjects across two Phase 1 studies.
    Zhu Y; Wang Q; Frederick B; Bouman-Thio E; Marini JC; Keen M; Petty KJ; Davis HM; Zhou H
    Clin Drug Investig; 2013 Apr; 33(4):291-301. PubMed ID: 23512638
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of two biosimilarity studies of FKB327 with the adalimumab reference product: randomized phase 1 studies of single-blind, single-dose subcutaneous injection in healthy Japanese male participants.
    Yonemura T; Yazawa R; Haranaka M; Kawakami K; Takanuma M; Kanzo T; Stefanidis D; Arai Y
    BMC Pharmacol Toxicol; 2022 Jan; 23(1):6. PubMed ID: 34998419
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized trial comparing LY01011, biosimilar candidate, with the reference product denosumab (Xgeva®) in healthy Chinese subjects.
    Ding Y; Liu Y; Dou C; Guo S
    J Bone Oncol; 2023 Oct; 42():100499. PubMed ID: 37701913
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of Pharmacokinetic Similarity, Immunogenicity, and Safety of Ustekinumab and BAT2206 in Healthy Chinese Male Subjects in a Double-Blind, Randomized, Single-Dose, Parallel-Group Phase I Trial.
    Wu M; Li X; Yang D; Wang M; Zhang H; Li C; Mai J; Yang L; Qi Y; Yu JC; Yang X; Wang Z; Gu C; Ding Y
    BioDrugs; 2023 Jan; 37(1):89-98. PubMed ID: 36417156
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Phase I, Randomized, Double-Blind, Single-Dose, Parallel-Group Study to compare Pharmacokinetic Similarity, Safety, and Immunogenicity Between BAT2506 and Golimumab in Healthy Chinese Male Subjects.
    Wu M; Sun J; Wu D; Xu J; Wei J; Wang Z; Yu J; Li S; Zhang H; Ding Y
    Expert Opin Investig Drugs; 2021 Jan; 30(1):77-83. PubMed ID: 33241960
    [No Abstract]   [Full Text] [Related]  

  • 12. A Phase I, Randomized, Single-Dose Study to Evaluate the Biosimilarity of HOT-3010 to Adalimumab Among Healthy Chinese Male Subjects.
    Zhang H; Chen H; Li X; Wu M; Zhu X; Li C; Liu J; Wei H; Hu Y; Wang J; Yang Y; Zhu X; Ding Y
    Front Pharmacol; 2021; 12():646171. PubMed ID: 34122068
    [No Abstract]   [Full Text] [Related]  

  • 13. Safety and pharmacokinetics of a new biosimilar trastuzumab (HL02): a Phase I bioequivalence study in healthy Chinese men.
    Zhang H; Liu T; Wu M; Wei H; Li C; Li X; Liu J; Chen H; Ding Y; Liu L
    Expert Opin Biol Ther; 2022 Feb; 22(2):179-186. PubMed ID: 33616478
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetic Similarity of ABP 654, an Ustekinumab Biosimilar Candidate: Results from a Randomized, Double-blind Study in Healthy Subjects.
    Chow V; Mytych DT; Das S; Franklin J
    Clin Pharmacol Drug Dev; 2023 Sep; 12(9):863-873. PubMed ID: 37415567
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Phase I, Randomized, Single-Dose Study to Evaluate the Biosimilarity of QL1206 to Denosumab Among Chinese Healthy Subjects.
    Zhang H; Wu M; Zhu X; Li C; Li X; Sun J; Liu C; Liu Q; Wei W; Niu J; Ding Y
    Front Pharmacol; 2020; 11():01329. PubMed ID: 33132906
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized, double-blind, single-dose, phase 1 study comparing the pharmacokinetics, pharmacodynamics, safety, and immunogenicity of denosumab biosimilar CT‑P41 and reference denosumab in healthy males.
    Kim A; Hong JH; Shin W; Yoo H; Jung JG; Reginster JY; Kim S; Bae Y; Suh J; Kim S; Lee E; Silverman S
    Expert Opin Biol Ther; 2024 Jul; 24(7):655-663. PubMed ID: 38349618
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Randomized Phase 1 Pharmacokinetic Study Comparing the Potential Biosimilar LRG201902 With Liraglutide (Victoza
    Mai G; Fan L; Li M; Zhang P; Gan C; Huang Q; Shentu J
    Front Pharmacol; 2020; 11():610880. PubMed ID: 33584289
    [No Abstract]   [Full Text] [Related]  

  • 18. A Randomized, Phase I Pharmacokinetic Study Comparing SB2 and Infliximab Reference Product (Remicade(®)) in Healthy Subjects.
    Shin D; Kim Y; Kim YS; Körnicke T; Fuhr R
    BioDrugs; 2015 Dec; 29(6):381-8. PubMed ID: 26577771
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and pharmacokinetics of a biosimilar of denosumab (KN012): Phase 1 and bioequivalence study in healthy Chinese subjects.
    Zhang H; Li C; Liu J; Wu M; Li X; Zhu X; Li Q; Wang B; Mao Y; Ding Y; Jin Q
    Expert Opin Investig Drugs; 2021 Feb; 30(2):185-192. PubMed ID: 33306418
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Phase I, Randomized, Single-Dose Study Evaluating the Biosimilarity of TAB008 to Bevacizumab in Healthy Volunteers.
    Wang J; Qi L; Liu L; Wang Z; Chen G; Wang Y; Liu X; Liu Y; Liu H; Tong Y; Liu C; Lei C; Wang X
    Front Pharmacol; 2019; 10():905. PubMed ID: 31474863
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.